Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator

被引:9
|
作者
Francia, Pietro [1 ]
Ziacchi, Matteo [2 ]
Adduci, Carmen [1 ]
Ammendola, Ernesto [3 ]
Pieragnoli, Paolo [4 ]
De Filippo, Paolo [5 ]
Rapacciuolo, Antonio [6 ]
Rella, Valeria [7 ]
Migliore, Federico [8 ]
Viani, Stefano [9 ]
Musumeci, Maria Beatrice [1 ]
Biagini, Elena [2 ]
Lovecchio, Mariolina [10 ]
Baldini, Rossella [1 ]
Falasconi, Giulio [11 ,12 ]
Autore, Camillo [1 ]
Biffi, Mauro [2 ]
Cecchi, Franco [4 ,7 ]
机构
[1] Univ Sapienza, St Andrea Hosp, Dept Clin & Mol Med, Cardiol, Rome, Italy
[2] Univ Bologna, Inst Cardiol, Dept Expt Diagnost & Specialty Med, Policlin S Orsola Malpighi, Bologna, Italy
[3] Univ Campania Luigi Vanvitelli, Monaldi Hosp, Dept Translat Med Sci, Naples, Italy
[4] Univ Florence, Careggi Univ Hosp, Florence, Italy
[5] Papa Giovanni XXIII Hosp, Bergamo, Italy
[6] Univ Naples Federico II, Dept Adv Biomed Sci, Naples, Italy
[7] San Luca Hosp, Ist Auxol Italiano, Dept Cardiovasc Neural & Metab Sci, IRCCS, Milan, Italy
[8] Univ Padua, Dept Cardiac Thorac Vasc Sci & Publ Hlth, Padua, Italy
[9] Univ Hosp Pisa, Cardiothorac & Vasc Dept, Cardiol Div 2, Pisa, Italy
[10] Boston Sci, Milan, Italy
[11] Univ Barcelona, Campus Clin, Barcelona, Spain
[12] IRCCS Humanitas Res Hosp, Milan, Italy
来源
EUROPACE | 2023年 / 25卷 / 09期
关键词
Hypertrophic cardiomyopathy; Implantable cardioverter-defibrillator; Subcutaneous implantable cardioverter-defibrillator; Device-related complications; SUDDEN CARDIAC DEATH; CARDIOVERTER-DEFIBRILLATOR; TASK-FORCE; INAPPROPRIATE SHOCKS; EUROPEAN-SOCIETY; PREVENTION; OUTCOMES; THERAPY; ICD; ASSOCIATION;
D O I
10.1093/europace/euad270
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims The implantable cardioverter-defibrillator (ICD) is a life-saving therapy in patients with hypertrophic cardiomyopathy (HCM) at risk of sudden cardiac death. Implantable cardioverter-defibrillator complications are of concern. The subcutaneous ICD (S-ICD) does not use transvenous leads and is expected to reduce complications. However, it does not provide bradycardia and anti-tachycardia pacing (ATP). The aim of this study was to compare appropriate and inappropriate ICD interventions, complications, disease-related adverse events and mortality between HCM patients implanted with a S- or transvenous (TV)-ICD.Methods and results Consecutive HCM patients implanted with a S- (n = 216) or TV-ICD (n = 211) were enrolled. Propensity-adjusted cumulative Kaplan-Meier curves and multivariate Cox proportional hazard ratios were used to compare 5-year event-free survival and the risk of events. The S-ICD patients had lower 5-year risk of appropriate (HR: 0.32; 95%CI: 0.15-0.65; P = 0.002) and inappropriate (HR: 0.44; 95%CI: 0.20-0.95; P = 0.038) ICD interventions, driven by a high incidence of ATP therapy in the TV-ICD group. The S- and TV-ICD patients experienced similar 5-year rate of device-related complications, albeit the risk of major lead-related complications was lower in S-ICD patients (HR: 0.17; 95%CI: 0.038-0.79; P = 0.023). The TV- and S-ICD patients displayed similar risk of disease-related complications (HR: 0.64; 95%CI: 0.27-1.52; P = 0.309) and mortality (HR: 0.74; 95%CI: 0.29-1.87; P = 0.521).Conclusion Hypertrophic cardiomyopathy patients implanted with a S-ICD had lower 5-year risk of appropriate and inappropriate ICD therapies as well as of major lead-related complications as compared to those implanted with a TV-ICD. Long-term comparative follow-up studies will clarify whether the lower incidence of major lead-related complications will translate into a morbidity or survival benefit. Graphical Abstract
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Clinical outcome in patients with hypertrophic cardiomyopathy and implantable cardioverter defibrillator therapy
    Schukro, C.
    Rosenhek, R.
    Pezawas, T.
    Stix, G.
    Kastner, J.
    Wolzt, M.
    Schmidinger, H.
    EUROPEAN HEART JOURNAL, 2009, 30 : 24 - 24
  • [22] SAFETY OF DEFIBRILLATOR IMPLANTATION IN PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
    ODONOGHUE, S
    PLATIA, E
    MISPIRETA, L
    BOYCE, S
    PANZA, J
    TRIPODI, D
    MCAREAVEY, D
    FANANAPAZIR, L
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, : A11 - A11
  • [23] Reply to: Is subcutaneous implantable cardioverter-defibrillator testing effective and safe for patients with hypertrophic cardiomyopathy?
    Maurizi, Niccolo
    Olivotto, Iacopo
    Cecchi, Franco
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 246 : 55 - 55
  • [24] Who Should Receive the Subcutaneous Implanted Defibrillator? Timing Is Not Right to Replace the Transvenous Implantable Cardioverter Defibrillator Response
    Poole, Jeanne E.
    Gold, Michael R.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2013, 6 (06): : 1251 - 1251
  • [25] Clinical Course and Management of Hypertrophic Cardiomyopathy
    Maron, Barry J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (07): : 655 - 668
  • [26] Clinical Course and Management of Hypertrophic Cardiomyopathy
    Bachmayer, Karl
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (20): : 1976 - 1976
  • [27] CLINICAL COURSE OF HYPERTROPHIC, OBSTRUCTIVE CARDIOMYOPATHY
    HESS, OM
    MATTHYS, HM
    LUSCHER, H
    ROTHLIN, ME
    SENNING, A
    KRAYENBUHL, HP
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1978, 108 (44) : 1716 - 1718
  • [28] RACIAL DIFFERENCES IN CLINICAL COURSE AND OUTCOME OF PATIENTS WITH HYPERTROPHIC CARDIOMYOPATHY
    Wells, Sophie B.
    Rowin, Ethan
    Bhatt, Viraj
    Maron, Martin
    Maron, Barry J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) : 906 - 906
  • [29] Prognosis of hypertrophic cardiomyopathy in Japanese patients with an implantable cardioverter defibrillator -focus on apical hypertrophic cardiomyopathy
    Nakano, M.
    Kondo, Y.
    Nakano, M.
    Kajiyama, T.
    Ito, R.
    Kitagawa, M.
    Sugawara, M.
    Chiba, T.
    Ryuzaki, S.
    Yoshino, Y.
    Kobayashi, Y.
    EUROPEAN HEART JOURNAL, 2022, 43 : 663 - 663
  • [30] Strength of clinical indication and therapeutic impact of the implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy
    Fumagalli, Carlo
    De Filippo, Valentina
    Zocchi, Chiara
    Tassetti, Luigi
    Marra, Martina Perazzolo
    Brunetti, Giulia
    Baritussio, Anna
    Cipriani, Alberto
    Bauce, Barbara
    Carrassa, Gianmarco
    Maurizi, Niccolo
    Zampieri, Mattia
    Calore, Chiara
    De Lazzari, Manuel
    Berteotti, Martina
    Pieragnoli, Paolo
    Corrado, Domenico
    Olivotto, Iacopo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2022, 353 : 62 - 67